Skip to main content

There is controversy about the outcomes of patients with superficial bladder cancer with or without adjuvant therapy after transurethral resection (TUR). One of the main issues is whether or not adjuvant chemotherapy or immunotherapy prevents progression to aggressive life-threatening cancer or just prevents relatively benign recurrences of superficial bladder cancers.

Physicians in Europe performed a clinical study to evaluate the role of adjuvant therapy in patients with superficial bladder cancer. Four hundred forty-three patients were treated with either TUR surgery alone, or TUR followed by adjuvant chemotherapy (doxorubicin and ethoglucid) instilled into the bladder for one year.

Adjuvant chemotherapy significantly prolonged the time to first recurrence of superficial bladder cancer. Unfortunately, progression to more invasive bladder cancer occurred in approximately 15% of patients irrespective of their treatment.

Adjuvant chemotherapy with doxorubicin and ethoglucid prevents superficial recurrences of bladder cancer but does not decrease the risk of progression to more invasive cancer. This is in contrast to clinical trials showing an approximate 10-15% decrease in progression to more invasive bladder cancer following the instillation of Bacillus Calmette-Guérin (BCG) immunotherapy. The results of this study support the use of BCG as initial therapy for the treatment of superficial bladder cancer. (Journal of Urology, Vol 158, No 2, pp 378-384, 1997)

Scroll to Continue

Recommended Articles

Image placeholder title

Kisqali Improves Survival in Premenopausal ER+ Advanced Breast Cancer

Kisqali prolongs survival for Pre-menopausal ER positive HER2 Neg breast cancer. San Antonio 2020 update.

Jemperli

GARNET Study Leads to FDA Approval for Jemperli for Uterine/Endometrial Cancer

Jemperli immunotherapy advances treatment of endometrial cancer, especially those with MSI-H or dMMR defects.